Drug Trial Radar · NCT01698476
Immune Reconstitution in Tuberculosis Disease
Last checked: Nov 19, 2026Latest source record: Feb 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
390
Actual
Start
Sep 2012
Primary completion
Aug 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- Karolinska InstitutetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Addis Ababa University; Armauer Hansen Research Institute, Ethiopia
- First posted
- Oct 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim with study is to provide adjunctive therapy with vitamin D and phenylbutyrate together with standard anti-tuberculosis treatment to significantly improve clinical recovery among patients with untreated, active pulmonary tuberculosis.
Conditions
- Pulmonary Tuberculosis (TB)
Interventions
vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)Drug
Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
Placebo tabletsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite clinical TB scoreTime frame: 0 (baseline) compared to 8 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine
Addis Ababa, Lideta sub city, Ethiopia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.